↓ Skip to main content

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma

Overview of attention for article published in BMC Cancer, December 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
33 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma
Published in
BMC Cancer, December 2012
DOI 10.1186/1471-2407-12-590
Pubmed ID
Authors

BP Fairfax, S Pratap, ISD Roberts, J Collier, R Kaplan, AM Meade, AW Ritchie, T Eisen, VM Macaulay, A Protheroe

Abstract

Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized RCC consists of surveillance-based follow up. The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 3%
Unknown 32 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 15%
Researcher 4 12%
Other 3 9%
Student > Ph. D. Student 3 9%
Student > Bachelor 2 6%
Other 8 24%
Unknown 8 24%
Readers by discipline Count As %
Medicine and Dentistry 12 36%
Agricultural and Biological Sciences 3 9%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Business, Management and Accounting 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 4 12%
Unknown 10 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2012.
All research outputs
#20,176,348
of 22,689,790 outputs
Outputs from BMC Cancer
#6,482
of 8,250 outputs
Outputs of similar age
#247,205
of 278,718 outputs
Outputs of similar age from BMC Cancer
#99
of 107 outputs
Altmetric has tracked 22,689,790 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,250 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,718 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.